Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BOPA 2018 | Update from the Scottish Cancer Medicines Outcome Programme

Kelly Baillie, of the NHS Greater Glasgow & Clyde, Glasgow, UK, presents the key findings from the Cancer Medicines Outcome Programme, a collaboration between NHS Greater Glasgow and Clyde and the University of Strathclyde with the aim of investigating whether medicines are as effective in real world populations, as they are in clinical trials. Looking specifically at men who received abiraterone and enzalutamide for the treatment of metastatic, castration-resistant prostate cancer, this initiative used electronic record linkage to combine the chemotherapy prescribing system with other useful patient information. At the British Oncology Pharmacy Association (BOPA) Annual Symposium 2018, held in Birmingham, UK, Ms Baillie shares the results of this retrospective study.